Sustained drug delivery implant
US10231926B2 · kind B2 · utility
1Cited by
139References
3Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Nov 14, 2016 |
| Grant date | Mar 19, 2019 |
| Priority date | — |
| Expiry date | Nov 14, 2036 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61F2210/0004
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Biocompatible intraocular implants may include a brimonidine free base and a biodegradable polymer associated with the brimonidine free base to facilitate the release of the brimonidine free base into an eye with the polymer matrix lasts a period of time of not more than twice the drug release duration, but more than the drug release duration.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.